Clarification of Details for Enhanced Rehabilitation System Addition in Recovery Phase, Drugs Excluded from Comprehensive Evaluation, and Special Meal Addition for Dysphagia Diet Adjustment – Doubt Interpretation 5 [FY2026 Medical Fee Revision] (2) – GemMed

News Highlights

In the 5th round of doubt interpretations regarding the FY2026 medical fee revision, details concerning the enhanced rehabilitation system addition in recovery phase rehabilitation wards, drugs excluded from comprehensive evaluation, and the special meal addition for dysphagia diet adjustment have been clarified. This suggests the importance of improving the quality of post-acute rehabilitation medical care and nutritional management tailored to individual patient conditions.

M&A Medical Editorial Department’s Perspective

This doubt interpretation specifically outlines the eligibility criteria for the “enhanced rehabilitation system addition” in recovery phase rehabilitation wards and the scope of the “special meal addition” that considers swallowing function. In particular, the clarification of the scope of drugs not subject to the comprehensive evaluation (DPC) in recovery phase rehabilitation wards is significant from the perspective of pharmaceutical cost management. Furthermore, the addition for dysphagia diet adjustment can be said to promote the enhancement of expertise in nutritional management and its appropriate evaluation. These revisions are directly linked to the management strategies of recovery phase rehabilitation wards and are key to securing profitability, especially for medical institutions aiming to build highly specialized medical provision systems. When considering M&A, the adaptability to such medical fee revisions and the ability to establish systems to meet the eligibility criteria will be indispensable factors in assessing the value of the target medical institution.

Points This News Highlights

• The necessity of analyzing the impact on revenue by concretizing the eligibility criteria for the “enhanced rehabilitation system addition” in recovery phase rehabilitation wards.
• The impact of clarifying drugs excluded from comprehensive evaluation (DPC) on pharmaceutical cost management strategies.
• The impact of expanding the scope of the “special meal addition” for dysphagia diet adjustment on investment decisions for nutritional management systems.
• The impact of adaptability to individual items of medical fee revisions on the business value assessment of recovery phase rehabilitation wards.

Practical Questions Arising from This News

• How specifically will the eligibility criteria for the enhanced rehabilitation system addition in recovery phase rehabilitation wards change with this revision?
• What kind of system development will be necessary to claim the special meal addition for dysphagia diet adjustment?
• Is it necessary to review the drug procurement strategy now that the scope of drugs excluded from DPC has been clarified?

If You Feel “Should I Consult Too?”

Medical institution managers who operate recovery phase rehabilitation wards and are not fully aware of how the details of this medical fee revision will specifically affect their institution’s revenue and operational structure, or who feel challenges in strengthening their systems to meet the eligibility criteria, are encouraged to consult with M&A specialists. You can receive concrete advice on analyzing your institution’s current situation, strategies for adapting to future medical fee revisions, and options for stabilizing management through business succession or group formation.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a full success fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are accepted with strict confidentiality. Free consultations are available here.